MYGN MYRIAD GENETICS INC
8-K Current Report
Filed: February 23, 2026
Health Care
In Vitro & In Vivo Diagnostic SubstancesMYRIAD GENETICS INC (MYGN) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q results press release referenced in this 8-K filing, signed February 23, 2026 by CFO Benjamin R. Wheeler
- • Actual financial figures contained in the exhibit (Ex. 99.1) — refer there for revenue, earnings, and guidance details
Get deeper insights on MYRIAD GENETICS INC
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.